Webinar

Can One Peptide Change Pain Research? Meet the Tool Transforming Drug Discovery

Discover how a new peptide tool, WRPRFa, is helping researchers better understand pain pathways and accelerate the search for next-generation analgesics.

Acid-sensing ion channels (ASICs) are proton-gated ion channels involved in both normal and disease processes. ASIC1a and ASIC3 are strongly linked to pain perception, but studying their individual roles has been hindered by a lack of highly selective pharmacological tools.

JScientific illustration of the human upper body with highlighted peripheral nerve pathways, symbolising nociceptor activity and pain transmission relevant to ASIC3 research.oin Dr Nien-Du Yang (Latigo Biotherapeutics) and Dr James Costantin (Eurofins DiscoverX) as they present new research on WRPRFa, a potent and selective peptide modulator of ASIC3. This novel tool helps researchers study ASIC3 activity with far greater precision, deepening our understanding of its role in pain pathways and its promise as a therapeutic target.

Together, these advances are strengthening the foundations of drug discovery, supporting progress from target validation through to preclinical development.

In this webinar, you’ll learn:

  1. How manual and automated patch-clamp platforms define structure–activity relationships of peptidic ion channel modulators.
  2. Why WRPRFa is a valuable selective tool for studying ASIC3 biology, a promising target in pain research and analgesic discovery.
  3. How electrophysiological data demonstrate the robustness and suitability of Eurofins DiscoverX ASIC3 cell lines for drug discovery.

Learn how WRPRFa is advancing pain research and analgesic discovery >>

SPEAKERS

Dr Nien-Du Yang

Dr Nien-Du Yang – Senior Scientist, Latigo Biotherapeutics, Inc

Nien-Du Yang earned his Ph.D. in Biomedical Engineering from Washington University in St. Louis, where he studied ion channel biophysics and pharmacology with a focus on voltage-gated potassium channels and their role in neuronal excitability. He joined Latigo Biotherapeutics in 2023, where he applies his expertise in ion channels and electrophysiology to the company’s drug discovery programs.

Dr James Costantin

Dr James Costantin – Scientific Market Development Manager – Ion Channels, Eurofins DiscoverX                 

Dr James Costantin began his career as an ion channel patch-clamper in academia. After earning a Ph.D. in Neuroscience from the University of Texas Medical School (M.D. Anderson Cancer Center), he completed electrophysiology postdoctoral research at UCLA and UC Berkeley. In 2002, he moved to industry, joining Molecular Devices as an Application Scientist and later Product Manager for the IonWorks line of automated patch-clamp (APC) instruments. He went on to join Nanion Technologies in 2015, supporting the SyncroPatch line of APC systems. Since 2022, James has been with Eurofins DiscoverX, where he manages the ion channel cell line product portfolio and oversees a fully functional ion channel laboratory utilizing a 384-well APC platform.

FAQs

Is the webinar free?
Yes – there is no charge to watch the webinar, either live or on-demand.

When will the webinar take place?
The webinar will take place live on 19 November 15:00 PM GMT. Now on demand. 

I’m busy. Can I watch it later?
The webinar will become available to watch on-demand shortly after the live webinar takes place.

What are the benefits of attending live?
During the live webinar, you’ll be able to ask the speakers your questions, which will then be answered during the live Q&A session towards the end of the webinar.

How long will the webinar be?
This webinar will last for up to one hour.

What do I need to watch this webinar?
All you need is a computer with an internet connection. Be sure to use headphones if in an office environment.

Do I receive a certificate?
Yes, you will receive a certificate if you attend the webinar live. The certificate will be sent with your on-demand video link.